Evaluation of Lipid Lowering Agents on Diabetic Retinopathy and Cardiovascular Risk of Diabetic Patients
Overview
- Phase
- Phase 4
- Intervention
- Fenofibrate 200mg
- Conditions
- Diabetic Retinopathy
- Sponsor
- Alaa Hassan ElBaz
- Enrollment
- 80
- Primary Endpoint
- The 80 participants will be evaluated through reduction of macular edema
- Last Updated
- 6 years ago
Overview
Brief Summary
The investigator study evaluate the effect of different lipid lowering agents on the progression of diabetic retinopathy and other reduction of cardiovascular risk of diabetic patients
Detailed Description
The investigator study compare the effect of lipid lowering agent on the enhancement of visual acuity and on reduction of macular edema in patients with diabetic retinopathy and also compare their effect on reduction of cardiovascular risk on diabetic patients via assessment of ASCVD risk score
Investigators
Alaa Hassan ElBaz
Assistant lecturer at beni suef university
Beni-Suef University
Eligibility Criteria
Inclusion Criteria
- •type 2diabetes
- •Non proliferative diabetic retinopathy
Exclusion Criteria
- •Uncontrolled glycemic level
- •proliferative diabetic retinopathy
Arms & Interventions
Receive oral hypoglycemic +fibrate
Fenofibrate +standard treatment
Intervention: Fenofibrate 200mg
Receive oral hypoglycemic +omega 3
Eicosapentanoic acid + standard treatment
Intervention: Omega 3 fatty acid
Receive oral hypoglycemic +statin
Simvastatin + standard treatment
Intervention: Simvastatin 40mg
Outcomes
Primary Outcomes
The 80 participants will be evaluated through reduction of macular edema
Time Frame: 18 weeks
assessed by ocular coherence tomography
Secondary Outcomes
- The 80 participants will be evaluated through reduction of cardiovascular risk(18 weeks)